The amniotic membrane of the placenta represents an exciting source of stem and stem-like cells, including human amnion epithelial cells (hAECs)-an easy-to-collect and abundant cell population possessing an embryonic stem cell-like differentiation capacity, potent immunomodulatory and anti-inflammatory properties 1 but, importantly, lacking tumorigenic potential. 2 Furthermore, hAECs are immuneprivileged, thereby exhibiting a low risk of host rejection upon transplantation. These advantageous characteristics have prompted the exploration of hAECs in therapies for conditions ranging from stroke 3 to lung diseases such as bronchopulmonary dysplasia (BPD), a common complication in premature infants. 4 Other related stem cells readily isolatable from the placenta include stem cells derived from the amniotic membrane and amniotic fluid, as well as mesenchymal stem cells (MSCs) derived from the placenta. As with MSC populations isolated from other tissues, placenta MSCs display multipotential differentiation capacity and potent immunomodulatory abilities and have been employed to promote angiogenesis in non-diabetic rodent models of hind limb ischemia at 2 to 3 weeks post-treatment 5 neuromorbidities. 4 In a previous study, researchers led by Atul Malhotra (Monash University, Clayton, VIC, Australia) evaluated the safety and tolerability of allogeneic hAECs in six premature infants with established severe BPD and described the immediate and short-term outcomes. 13 Now, the team returns with a STEM CELLS Translational Medicine article, in which they report on the longer-term safety outcomes of these infants. 6 Premature infants previously received hAECs intravenously, with the long-term follow-up data revealing that all but one infant survived to the evaluation endpoint and that these five infants were weaned off oxygen at a median time of 24 months. Magnetic resonance imaging of the brain established the presence of mild to moderate white matter loss, and the neurodisabilities diagnosed included hemiplegic cerebral palsy, global developmental delay, and severe hearing loss. However, the authors failed to observe evidence of tumor formation following hAEC administration or any long-term adverse events that could be attributed to hAEC administration. Overall, these findings establish the safety of low-dose allogeneic hAEC administration in vulnerable premature infants. Ongoing studies will aim to elucidate the optimum dosage and timing of hAEC administration toward optimizing treatment outcomes for BPD patients.
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Hybrid Scaffold-Induced Differentiation of Human MSCs Favors Bone Regrowth Patients
The osteoinduction of MSCs cultured on advanced scaffolding mate- ing to the loss of osteogenic differentiation and an increase in MSC adipogenesis. In summary, this study linked the dysregulation of an epigenetic control mechanism in MSCs to age-associated osteoporosis and obesity, thereby highlighting the targeting of the EZH2-HDAC9c axis as a potential therapeutic approach to conditions that affect over ten million individuals worldwide and suppose a serious economic burden.
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